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E-mail address: mrsmajidi55@yahoo.com (M. SeyyBackground & study aims: Selection of the best drug regimens for eradication of Helicobacter pylori infec-
tion especially in patients at risk of peptic ulcer relapses and the development of complications is chal-
lenging. This study assessed and compared the efﬁcacy of the two common PPI based triple therapies to a
quadruple therapy including PPI, metronidazole, amoxicillin and a bismuth compound in Iranian popu-
lation.
Patients & Methods: Three hundred and thirty patients with peptic ulcer and H. pylori infection were
included in the study. Patients were randomly assigned to one of the three treatment protocols all given
twice daily: (a) A 14-day quadruple therapy (OMAB group) comprising omeprazole 20 mg, metronicazole
500 mg, amoxicillin 1 g, and bismuth subcitrate 240 mg; (b) A 14-day triple regimen (OCP group) com-
prising omeprazole 20 mg plus clarithromycine 500 mg and penbactam 750 mg and (c) A 14-day triple
regimen (OCA group) comprising omeprazole 20 mg plus clarithromycine 500 mg and amoxicillin 1 g.
Cure was deﬁned as a negative urea breath test at least six weeks after treatment.
Results: The per-protocol eradication rates achieved with both OCP regimen (87.0%) and OCA treatment
(90.8%) were signiﬁcantly higher than the OMAB treatment protocol (56.0%); however, no signiﬁcant dif-
ference emerged in eradication rates between the two triple treatment schedules. No signiﬁcant differ-
ences between the groups were found in most side-effects.
Conclusion: Two-week quadruple therapy showed a lower eradication rate compared to common triple
treatment schedules when used as ﬁrst-line eradication treatment for H. pylori infection in Iranian
population.
 2012 Arab Journal of Gastroenterology. Published by Elsevier B.V. All rights reserved.Introduction
Selection of the best drug regimens for effective eradication of
Helicobacter pylori (H. pylori) infection especially in patients at risk
of peptic ulcer relapses and the development of complications of
peptic ulcer disease is already challenging. Nowadays, quadruple
therapy including classical triple therapy plus a proton pump
inhibitor (PPI) has been produced as an effective drug regimen
and even an alternative ﬁrst-line treatment for eradicating H. pylori
infection especially in areas of high prevalence of antibiotic
resistance. Some recent studies suggested that the effectiveness,
compliance and side effects of quadruple regimen including a gas-
tric acid inhibitor, a bismuth compound and amoxicillin might be
comparable with PPI-based triple therapy when administered as
ﬁrst-line treatment for H. pylori infection [1–4]. However, somef Gastroenterology. Published by El
.
edmajidi).others could show slight differences in effectiveness, usually in fa-
vour of quadruple therapy [5,6].
Besides, the eradication rates of different treatment schedules
for H. pylori infection are potentially dependent on the duration
of drug administration. It has been suggested that 1-week triple
and quadruple therapy can lead to similar efﬁcacy when used as
a ﬁrst-line eradication treatment [7]. Furthermore, although some
studies showed that the eradication rates of quadruple therapy
could be signiﬁcantly increased when it was given for 10–14 days
[8], it has been also indicated that 1-week quadruple therapy may
not be different from a 2-week regimen as an option for H. pylori
eradication [9].
Therefore, the advantages of quadruple therapy at present do
not seem clear enough to change current policies for H. pylori treat-
ment. Further, the effect of prolonging the length of quadruple
therapy on treatment efﬁcacy is already questioned.
The aim of the study was to assess and compare the efﬁcacy of
the two PPI-based triple therapies to a quadruple therapy includingsevier B.V. All rights reserved.
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Iranian population.Patients and methods
A prospective double-blinded randomised clinical trial study
was conducted on 330 patients referred to Taleghani Hospital in
Tehran from March 2007 to September 2011. All patients signed
an informed consent form. This research was approved by the
Ethics Committee of the Research Center for Gastroenterology
and Liver Disease in the Shahid Beheshti University of Medical
Sciences.
Patients had not been previously treated for H. pylori infection.
Subjects were excluded if they had been taking non-steroidal anti-
inﬂammatory drugs (NSAIDs), PPI, bismuth preparations or antibi-
otics during the previous 4 weeks. Pregnant women and patients
with a history of gastric surgery, renal and hepatic impairment
were not enrolled. Dyspepsia was deﬁned as epigastric pain or dis-
comfort lasting for at least 3 months. All patients were diagnosed
to be H. pylori positive by histopathological examination. Gastros-
copy was done using a videoscope (Olympus GIF-XQ260, Japan).
Two specimens were obtained from the antrum.
Patients were randomly assigned (110 patients in each group)
using a computer-generated list to one of the three treatment pro-
tocols: (a) a 14-day quadruple therapy (OMAB group) comprising
omeprazole 20 mg, metronidazole 500 mg, amoxicillin 1 g and bis-
muth subcitrate 240 mg, all given twice daily; (b) a 14-day triple
regimen (OCP group) comprising omeprazole 20 mg plus clarithro-
mycin 500 mg and penbactam 750 mg, all given twice daily and (c)
a 14-day triple regimen (OCA group) comprising omeprazole
20 mg plus clarithromycin 500 mg and amoxicillin 1 g, all given
twice daily. Patients were asked to return at the end of the treat-
ment to assess compliance with therapy that was deﬁned as con-
sumption of greater than 90% of the prescribed drugs.
Medications were discontinued if any intolerable adverse events
such as fever, urticarial rash or generalised body pain occurred. A
13C-urea breath test was performed for eradication assessmentTable 1
Demographic characteristics and clinical data of studied patients.
Characteristics OMAB group (n = 100) OCP g
Male gender 40 (40.0) 50 (5
Age (years) 44.0 ± 3.2 43.4 ±
Hypertension 17 (17.0) 19 (1
Diabetes mellitus 10 (10.0) 11 (1
Cigarette smoking 11 (11.0) 12 (1
Alcohol use 2 (2.0) 2 (2.0
Data are presented as mean ± SD or n (%).
p-value 6 0.05 as signiﬁcant.
Table 2
Endoscopy report and pathological ﬁndings in studied patients.
Characteristics OMAB group (n = 100) OCP
Endoscopy report
Gastroduodenitis 98 (98.0) 97 (
Gastric ulcer 16 (16.0) 20 (
Gastroduodenal ulcer 2 (2.0) 1 (1
Duodenal ulcer 20 (20.0) 21 (
Pathological ﬁndings
Gastritis 100 (100) 100
Intestinal metaplasia 9 (9.0) 7 (7
Dysplasia 2 (2.0) 2 (2
Data are presented as n (%).
p-Value 6 0.05 as signiﬁcant.6 weeks after completion of the treatment. The results of treatment
were evaluated with per-protocol analysis (which included only
patients who completed the study).
Statistical analysis was performed with the chi-squared test as
well as Fisher’s exact test, and the one-way analysis of variance
(ANOVA) test. P values of 0.05 or less were considered statistically
signiﬁcant. All the data were analysed using Statistical Package for
Social Sciences (SPSS) 16 for Windows (SPSS Inc., Chicago, IL, USA)
and the values were expressed as mean ± standard deviation (SD)
for continuous variables and percentages for categorical variables.Results
Among 110 patients in each group, 100 patients in the OMAB
group (90.9%), 100 patients in the OCP group (90.9%) and 98 pa-
tients in the OCA group (89.1%) would continued treatment proto-
cols and underwent 13C-urea breath testing. All patients included
into the study were ranged between 18 and 81 years and 48.7%
of them were male. The three studied groups were matched for
sex, age and general risk factors such as hypertension, diabetes
mellitus, current cigarette smoking and alcohol use (Table 1). The
most common endoscopic ﬁnding in the three groups was gastro-
duodenitis, whereas gastroduodenal ulcer was rarely reported in
each group. Regarding pathological ﬁndings, all patients suffered
from gastritis and other ﬁndings such as intestinal metaplasia
and dysplasia were less common in patients. Three treatment
groups were similar in terms of reported endoscopic and patholog-
ical ﬁndings (Table 2).
The per-protocol eradication rates achieved with both the OCP
regimen (87.0%) and the OCA treatment (90.8%) were signiﬁcantly
higher than the OMAB treatment protocol (56.0%); however, no
signiﬁcant difference emerged in eradication rates between the
two triple treatment schedules (Fig. 1).
Totally, per-protocol eradication rate of H. pylori in all studied
men and women was 76.6% and 79.1%, respectively. No signiﬁcant
differences were found in eradication rates between the two gen-
ders in each treatment group (Table 3). However, in both genders,roup (n = 100) OCA group (n = 98) p-value
0.0) 55 (56.1) 0.398
2.8 43.3 ± 3.3 0.644
9.0) 17 (17.3) 0.947
1.0) 10 (10.2) 0.976
2.0) 10 (10.2) 0.937
) 0 (0.0) 0.551
group (n = 100) OCA group (n = 98) p-Value
97.0) 94 (95.9) 0.998
20.0) 20 (20.4) 0.765
.0) 1 (1.0) 0.999
21.0) 21 (21.4) 0.984
(100) 98 (100) –
.0) 6 (6.1) 0.763
.0) 1 (1.0) 0.999
Fig. 1. Rate of H. pylori eradication in studied patients.
Table 3
Positive eradication rates in the three schedules in men and women.
Treatment group Men with PER (n = 111) Women with PER (n = 121) p-Value
OMAB therapy (n = 100) 20/40 (50.0) 36/60 (60.0) 0.598
OCP therapy (n = 100) 41/50 (82.0) 46/50 (92.0) 0.695
OCA therapy (n = 98) 50/55 (90.9) 39/43 (90.7) 0.994
p-Value 0.049 0.039
PER: positive eradication rate.
Data are presented as number (percentage).
Table 4
Drug side effects in studied patients.
Characteristics OMAB group (n = 100) OCP group (n = 100) OCA group (n = 98) p-Value
Dyspepsia 13 (13.0) 10 (10.0) 12 (12.2) 0.830
Diarrhoea 8 (8.0) 6 (6.0) 14 (14.3) 0.171
Nausea 14 (14.0) 10 (10.0) 11 (11.2) 0.728
Abdominal pain 9 (9.0) 6 (6.0) 11 (11.2) 0.486
Stool abnormality 14 (14.0) 8 (8.0) 7 (7.1) 0.278
Dizziness 4 (4.0) 2 (2.0) 2 (2.0) 0.738
Headache 6 (6.0) 3 (3.0) 8 (8.2) 0.330
Cough 2 (2.0) 1 (1.0) 2 (2.0) 0.874
Bad taste 3 (3.0) 35 (35.0) 37 (37.8) <0.001
Metallic taste 15 (15.0) 2 (2.0) 5 (5.1) 0.003
Data are presented as n (%).
p-Value 6 0.05 as signiﬁcant.
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signiﬁcantly lower than in groups with triple therapies. Common
side effects are shown in Table 4. No signiﬁcant differences werefound in drug side effects in the three groups except for bad taste
and metallic taste that were more common in OCA and OMAB
groups, respectively.
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H. pylori infection is usually eradicated by using multi-drug
regimens. Recently, quadruple drug therapies using a PPI with bis-
muth triple therapy has been recommended to decrease failure
rates of H. pylori eradication caused by resistance to some antibi-
otics such as metronidazole and clarithromycin [2]. However, the
present study could show that the eradication rates achieved with
both 2 weeks’ PPI-based triple regimens comprising penbactam or
amoxicillin were higher than PPI-based quadruple therapy includ-
ing metronidazole, amoxicillin and bismuth subcitrate. In our
study, a per-protocol eradication rate in quadruple therapy was
56.0%. A review of similar studies showed an eradication rate
ranging between 57.5% and 92% following 2-week triple therapies
and between 70.0% and 96% following 2-week quadruple thera-
pies that all were higher than our ﬁnding [7,9–13]. Further,
regarding the low susceptibility of H. pylori infection to metroni-
dazole, administration of quadruple therapy containing this anti-
biotic has been recommended as a second-line choice for H.
pylori eradication [13]. It seems that low cure rates following qua-
druple therapy in our study group can be due to antimicrobial
drug resistance, which is a main source of treatment failure fol-
lowing these regimens. Broad or inappropriate use of potent anti-
biotics in our hospitals results in low susceptibility of H. pylori to
some common antibiotics such as amoxicillin and metronidazole
in our population that can lead to development of antibiotic resis-
tance. Therefore, other regimens such as tetracycline-containing
quadruple rescue therapy are more recommended instead of
treatment comprising amoxicillin. It has been shown that tetracy-
cline-containing quadruple therapy is highly effective in treating
H. pylori eradication failures of the amoxicillin-containing regimen
[14]. Although the obtained eradication rates following both triple
schedules were comparable with other previous studies, we found
lower eradication rates of H. pylori infection following experi-
enced quadruple drug therapy. In a similar study by Clavet
et al., per-protocol cure rates were 86% for OCA triple therapy
and 89% for quadruple therapy including PPI, tetracycline chloride,
metronidazole and bismuth that was not signiﬁcantly different
between the two groups [5]. However, an eradication rate of
72.7% in the recent 2 years necessitates the development of a
more efﬁcient eradication regimen [15]. The results of the recent
studies provided support for the equivalence of triple and quadru-
ple therapies in terms of effectiveness and compliance when
administered as ﬁrst-line treatment for H. pylori infection. More-
over, the new protocol using ampicillin–sulbactam instead of
amoxicillin in the quadruple regimen is a suitable ﬁrst-line alter-
native to be used in regions with amoxicillin-resistant H. pylori
strains [16]. However, some research for comparing PPI-based tri-
ple and quadruple therapies found similar eradication rates fol-
lowing 1-week and 2-week drug administrations [4,7] and by
some others, quadruple therapy using a PPI was well tolerated
and signiﬁcantly superior to an alternative PPI-based triple ther-
apy especially in patients with older ages [12,17,18].
Although we used a 2-week drug regimen for bacteria eradica-
tion, some studies suggested no differences in the eradication rate
and tolerance between 1-week and 2-week regimens [9]. However,
relation between treatment efﬁcacy and duration of drug adminis-
tration was also found in some other studies. Fischbach et al.
showed similar treatment success for quadruple schedule given
for 4 or 7 days; however, these were 6% less effective than those gi-
ven for 10–14 days [8]. Prolonging therapy to 14 days increases the
eradication to some degree; per-protocol eradication rates ap-
proach 90% [19]. Besides, the disadvantages of prolonged quadru-
ple therapies were also discussed. A major disadvantage of
quadruple therapy is its complicated dosage. Reduced quadrupletherapy regimens administered thrice daily for 7 days, or even
twice daily for 14 days, have been shown to be highly effective in
pilot studies, and may improve treatment compliance [20,21].
Moreover, it seems that prolonging therapy is not a cost-effective
strategy because the increase in effectiveness is modest, and does
not outweigh the marked increase in drug expenses.
We also found that most of the drug-induced side effects were
comparable in triple and quadruple anti-H. pylori regimens and
only the bad taste-related side effect was different between the
two regimens. Findings of other surveys in terms of treatment side
effects were varied. In some of them, a similarity of side effects in
the two regimens was shown [7,10,12]. Besides, in some others,
the side effects tended to be more frequent in triple therapy than
in quadruple therapy [1]. It seems that the occurrence of side ef-
fects is directly dependent on the type and duration of drug con-
sumption. An increased rate of side effects with quadruple
therapy using higher metronidazole doses was reported [22,23].
The combination of bismuth subsalicylate or subcitrate with met-
ronidazole and tetracycline or amoxicillin also accompanied by the
complexity and relatively a high rate of side effects, but these ef-
fects can be surpassed by PPI-based regimens [24–26]. Further,
no signiﬁcant differences were found in eradication rates between
the two genders in each treatment protocol.
In conclusion, we found that PPI-based quadruple therapy had
no higher eradication rate in comparison with PPI-based triple
therapies. The superiority of 2-week triple therapy to 2-week qua-
druple protocol can be due to the low susceptibility of H. pylori to
administered drugs such as metronidazole or amoxicillin in the
second regimen and also low resistance of used antibiotics such
as clarithromycin or penbactam in triple therapy among our popu-
lation. Furthermore, similar side effects following triple and qua-
druple therapies can emphasise the administration of triple
treatment because of its less complexity and more cost
effectiveness.Conﬂict of interest
The authors declared that there was no conﬂict of interest.References
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